Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

Peer Review reports

Original Submission
8 Sep 2022	Submitted	Original manuscript
24 Feb 2023	Reviewed	Reviewer Report - Dieter Hoersch
24 Feb 2023	Reviewed	Reviewer Report
28 Feb 2023	Reviewed	Reviewer Report
5 Mar 2023	Reviewed	Reviewer Report
22 Mar 2023	Author responded	Author comments - Francesca Corti
Resubmission - Version 2
22 Mar 2023	Submitted	Manuscript version 2
2 Aug 2023	Reviewed	Reviewer Report
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
9 Aug 2023	Editorially accepted
26 Sep 2023	Article published	10.1186/s12885-023-11287-2

Back to article page